| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 3 | +33.33% | +4.49% | +0.75% | +3.74% | +2.91% | — |
| 14d | 3 | +33.33% | +3.81% | +0.11% | +3.70% | +3.31% | — |
| 30d | 3 | +0.00% | +11.43% | -0.72% | +12.14% | +20.97% | — |
| 60d | 3 | +0.00% | +30.84% | +3.13% | +27.71% | +53.36% | — |
| 90d | 3 | +0.00% | +44.24% | +6.59% | +37.65% | +59.95% | — |
| 180d | 3 | +33.33% | +86.20% | +10.95% | +75.25% | +106.05% | — |
| 1y | 3(2 pending) | +100.00% | +94.78% | +18.63% | +76.15% | +76.15% | — |
| 2y | 3(3 pending) | — | — | — | — | — | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| NVAX NOVAVAX INC | PURCHASEGRANT Stock grant | 21,270 | — | — | 21,270 | Jun 18, 2026 | Jun 23, 2026 ↗ | View → |
| NVAX NOVAVAX INC | PURCHASEGRANT Stock grant | 14,180 | — | — | 14,180 | Jun 18, 2026 | Jun 23, 2026 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 550 | $10.04 | $5.5K | 12,665 | Jun 11, 2026 | Jun 15, 2026 ↗ | View → |
| CHRS COHERUS ONCOLOGY, INC. | PURCHASEGRANT Stock grant | 60,000 | — | — | 60,000 | Jun 5, 2026 | Jun 9, 2026 ↗ | View → |
| CHRS COHERUS ONCOLOGY, INC. | PURCHASEGRANT Stock grant | 30,000 | — | — | 30,000 | Jun 5, 2026 | Jun 9, 2026 ↗ | View → |
| NVAX NOVAVAX INC | PURCHASE | 9,520 | — | — | 9,520 | Apr 25, 2026 | Apr 28, 2026 ↗ | View → |
| NVAX NOVAVAX INC | SALE | 9,520 | — | — | 19,040 | Apr 25, 2026 | Apr 28, 2026 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 14,788 | — | — | 14,788 | Mar 9, 2026 | Mar 11, 2026 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 13,215 | — | — | 13,215 | Mar 9, 2026 | Mar 11, 2026 ↗ | View → |
| LYEL LYELL IMMUNOPHARMA, INC. | SALE Chief Financial Officer | 1,453 | $10.54 | $15.3K | 15,306 | Aug 21, 2025 | Aug 22, 2025 ↗ | View → |
| LYEL LYELL IMMUNOPHARMA, INC. | PURCHASEGRANT Stock grant | 8,000 | — | — | 16,759 | Aug 20, 2025 | Aug 22, 2025 ↗ | View → |
| LYEL LYELL IMMUNOPHARMA, INC. | SALE Chief Financial Officer | 136 | $10.34 | $1.4K | 8,759 | Aug 12, 2025 | Aug 13, 2025 ↗ | View → |
| LYEL LYELL IMMUNOPHARMA, INC. | SALE Chief Financial Officer | 131 | $10.53 | $1.4K | 8,895 | Aug 11, 2025 | Aug 13, 2025 ↗ | View → |
| CHRS COHERUS ONCOLOGY, INC. | PURCHASEGRANT Stock grant | 112,000 | — | — | 112,000 | Jun 12, 2025 | Jun 13, 2025 ↗ | View → |
| NVAX NOVAVAX INC | PURCHASEGRANT Stock grant | 42,840 | — | — | 42,840 | Apr 25, 2025 | Apr 29, 2025 ↗ | View → |
| NVAX NOVAVAX INC | PURCHASEGRANT Stock grant | 28,560 | — | — | 28,560 | Apr 25, 2025 | Apr 29, 2025 ↗ | View → |
| LYEL LYELL IMMUNOPHARMA, INC. | PURCHASE Chief Financial Officer | 200,000 | $0.56 | $111.6K | 200,000 | Mar 17, 2025 | Mar 18, 2025 ↗ | View → |
| LYEL LYELL IMMUNOPHARMA, INC. | PURCHASEGRANT Stock grant | 56,250 | — | — | 56,250 | Feb 10, 2025 | Feb 26, 2025 ↗ | View → |
| LYEL LYELL IMMUNOPHARMA, INC. | PURCHASEGRANT Stock grant | 450,000 | — | — | 450,000 | Feb 10, 2025 | Feb 26, 2025 ↗ | View → |
| LYEL LYELL IMMUNOPHARMA, INC. | PURCHASEGRANT Stock grant | 112,500 | — | — | 172,725 | Feb 10, 2025 | Feb 26, 2025 ↗ | View → |
| CHRS COHERUS ONCOLOGY, INC. | PURCHASEGRANT Stock grant | 112,000 | — | — | 112,000 | Jun 3, 2024 | Jun 5, 2024 ↗ | View → |
| LYEL LYELL IMMUNOPHARMA, INC. | PURCHASEGRANT Stock grant | 40,000 | — | — | 48,729 | Feb 9, 2024 | Feb 13, 2024 ↗ | View → |
| LYEL LYELL IMMUNOPHARMA, INC. | PURCHASEGRANT Stock grant | 400,000 | — | — | 400,000 | Feb 9, 2024 | Feb 13, 2024 ↗ | View → |
| LYEL LYELL IMMUNOPHARMA, INC. | SALE Chief Financial Officer | 500,000 | — | — | 0 | Nov 16, 2023 | Nov 20, 2023 ↗ | View → |
| LYEL LYELL IMMUNOPHARMA, INC. | PURCHASEGRANT Stock grant | 500,000 | — | — | 500,000 | Nov 16, 2023 | Nov 20, 2023 ↗ | View → |
| LYEL LYELL IMMUNOPHARMA, INC. | PURCHASEGRANT Stock grant | 190,000 | — | — | 190,000 | Nov 16, 2023 | Nov 20, 2023 ↗ | View → |
| LYEL LYELL IMMUNOPHARMA, INC. | SALE Chief Financial Officer | 516,000 | — | — | 0 | Nov 16, 2023 | Nov 20, 2023 ↗ | View → |
| LYEL LYELL IMMUNOPHARMA, INC. | SALE Chief Financial Officer | 190,000 | — | — | 0 | Nov 16, 2023 | Nov 20, 2023 ↗ | View → |
| LYEL LYELL IMMUNOPHARMA, INC. | SALE Chief Financial Officer | 3,612,000 | — | — | 0 | Nov 16, 2023 | Nov 20, 2023 ↗ | View → |
| LYEL LYELL IMMUNOPHARMA, INC. | PURCHASEGRANT Stock grant | 3,612,000 | — | — | 3,612,000 | Nov 16, 2023 | Nov 20, 2023 ↗ | View → |
| LYEL LYELL IMMUNOPHARMA, INC. | PURCHASEGRANT Stock grant | 516,000 | — | — | 516,000 | Nov 16, 2023 | Nov 20, 2023 ↗ | View → |
| CHRS COHERUS ONCOLOGY, INC. | PURCHASEGRANT Stock grant | 38,250 | — | — | 38,250 | Jun 7, 2023 | Jun 9, 2023 ↗ | View → |
| LYEL LYELL IMMUNOPHARMA, INC. | PURCHASEGRANT Stock grant | 700,000 | — | — | 700,000 | Feb 24, 2023 | Feb 28, 2023 ↗ | View → |
| CHRS COHERUS ONCOLOGY, INC. | PURCHASEGRANT Stock grant | 54,000 | — | — | 54,000 | May 4, 2022 | May 6, 2022 ↗ | View → |
| LYEL LYELL IMMUNOPHARMA, INC. | PURCHASEGRANT Stock grant | 500,000 | — | — | 500,000 | Mar 16, 2022 | Mar 18, 2022 ↗ | View → |